Effect of a platelet-activating factor antagonist on pancreatitis-associated gut barrier dysfunction in rats.
Platelet-activating factor (PAF) may play a critical and primary role in the pathogenesis of acute pancreatitis and pancreatitis-associated distant organ injury. The present study evaluated the effect of a PAF antagonist, lexipafant (an (S)-4-methyl-2[methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-benzene sulphonyl]-amino]pentanoic acid ethyl ester, BB-882; British Biotech Ltd.), on the potential prevention of gut barrier dysfunction, by measuring gut origin sepsis, bidirectional permeability of the intestinal barrier, and pancreatic capillary endothelial barrier integrity, in acute pancreatitis induced by intraductal infusion of 5% sodium taurodeoxycholate. Pancreatic endothelial permeability significantly increased in animals with acute pancreatitis, whereas pretreatment with lexipafant had a preventive effect (p < 0.05 vs. pancreatitis with saline). Similarly, alterations noted in hematocrit and plasma levels of lipase and calcium were counteracted by the PAF antagonist. It also prevented the increase in albumin leakage from blood to the mucosal interstitium and from blood to the intestinal lumen in acute pancreatitis. Albumin passage from the gut lumen to blood in animals with pancreatitis pretreated with saline increased from 3 h and on, and lexipafant prevented alterations in mucosal epithelial permeability. Bacterial translocation was commonly seen in pancreatitis, whereas only a few positive cultures were observed in pancreatitis animals given lexipafant. Microthrombosis in intestinal villi seemed less frequent after lexipafant pretreatment. We conclude that (a) PAF may play a role in the pathogenesis of pancreatitis-associated intestinal dysfunction, (b) PAF may be involved in the development of distant organ dysfunction by triggering endothelial barrier dysfunction, and (c) PAF antagonists may provide potential agents for preventing pancreatitis-associated gut barrier dysfunction.
Department of Surgery, Lund University Hospital, Sweden.
R
R
Andersson
X
X
Wang
Z
Z
Sun
X
X
Deng
V
V
Soltesz
I
I
Ihse
D000208:Acute Disease; D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects; D002118:Calcium / Q000097:blood; D002199:Capillary Permeability / Q000502:physiology; D004730:Endothelium, Vascular / Q000503:physiopathology; D004755:Enterobacteriaceae / Q000302:isolation & purification / Q000502:physiology; D006400:Hematocrit; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000098:blood supply / Q000382:microbiology / Q000503:physiopathology*; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008049:Lipase / Q000097:blood; D008297:Male; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects; D010195:Pancreatitis / Q000139:chemically induced / Q000382:microbiology / Q000503:physiopathology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013657:Taurodeoxycholic Acid
D007093:Imidazoles; D010972:Platelet Activating Factor; D013657:Taurodeoxycholic Acid; D008049:Lipase; D007930:Leucine; C103289:lexipafant; D002118:Calcium